

ANGIODYNAMICS INC  
Form 10-Q  
April 09, 2009  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

**x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended February 28, 2009

OR

**.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-50761

**AngioDynamics, Inc.**

(Exact name of registrant as specified in its charter)

Edgar Filing: ANGIODYNAMICS INC - Form 10-Q

<b>Delaware</b> (State or other jurisdiction of incorporation or organization)	<b>11-3146460</b> (I.R.S. Employer Identification No.)
<b>603 Queensbury Ave., Queensbury, New York</b> (Address of principal executive offices)	<b>12804</b> (Zip Code)
<b>(518) 798-1215</b> Registrant's telephone number, including area code	

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input checked="" type="checkbox"/>
Non-accelerated filer <input type="checkbox"/>	Smaller reporting company <input type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the Issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding as of April 3, 2009
Common Stock, par value \$.01	24,426,118 shares

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**INDEX**

	<b>Page</b>
<b><u>Part I: Financial Information</u></b>	
Item 1. <u>Financial Statements</u>	
<u>Consolidated Balance Sheets February 28, 2009 (unaudited) and May 31, 2008</u>	3
<u>Consolidated Statements of Income three and nine months ended February 28, 2009 and February 29, 2008 (unaudited)</u>	4
<u>Consolidated Statement of Stockholders Equity and Comprehensive Income nine months ended February 28, 2009 (unaudited)</u>	5
<u>Consolidated Statements of Cash Flows nine months ended February 28, 2009 and February 29, 2008 (unaudited)</u>	6
<u>Notes to Consolidated Financial Statements (unaudited)</u>	7 18
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	19 27
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	28
Item 4. <u>Controls and Procedures</u>	29
<b><u>Part II: Other Information</u></b>	
Item 1. <u>Legal Proceedings</u>	30
Item 1A. <u>Risk Factors</u>	31
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	31
Item 3. <u>Defaults Upon Senior Securities</u>	31
Item 4. <u>Submission of Matters to a Vote of Security Holders</u>	31
Item 5. <u>Other Information</u>	31
Item 6. <u>Exhibits</u>	32

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****CONSOLIDATED BALANCE SHEETS**

(in thousands, except share data)

	February 28, 2009 (unaudited)	May 31, 2008
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$ 26,776	\$ 32,040
Restricted cash		68
Marketable securities, at fair value	35,557	46,182
Total cash, cash equivalents and marketable securities	62,333	78,290
Accounts receivable, net of allowance for doubtful accounts of \$573 and \$683, respectively	26,501	26,642
Inventories, net	32,415	22,901
Deferred income taxes	8,063	10,902
Prepaid expenses and other	5,305	3,147
Total current assets	134,617	141,882
PROPERTY, PLANT AND EQUIPMENT-AT COST, less accumulated depreciation	22,600	21,163
OTHER ASSETS	875	1,865
INTANGIBLE ASSETS, less accumulated amortization	70,065	71,311
GOODWILL	161,990	162,707
DEFERRED INCOME TAXES	7,425	6,860
PREPAID ROYALTIES	3,007	2,959
TOTAL ASSETS	\$ 400,579	\$ 408,747
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 9,871	\$ 9,081
Accrued liabilities	10,499	9,523
Income taxes payable		933
Current portion of long-term debt and convertible note	350	10,040
Litigation provision		6,757
Other current liabilities, net of discount	5,164	5,000
Total current liabilities	25,884	41,334
LONG-TERM DEBT, net of current portion	6,810	7,075
OTHER LONG TERM LIABILITIES, net of discount		4,625
Total liabilities	32,694	53,034
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>STOCKHOLDERS EQUITY</b>		
Preferred stock, par value \$.01 per share, 5,000,000 shares authorized; no shares issued and outstanding		
Common stock, par value \$.01 per share, 45,000,000 shares authorized; issued and outstanding 24,426,118 and 24,268,266 shares, respectively	245	243
Additional paid-in capital	356,765	350,598

Edgar Filing: ANGIODYNAMICS INC - Form 10-Q

Retained earnings	11,938	4,908
Accumulated other comprehensive loss	(1,063)	(36)
Total stockholders' equity	367,885	355,713
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 400,579</b>	<b>\$ 408,747</b>

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****CONSOLIDATED STATEMENTS OF INCOME****(unaudited)****(in thousands, except per share data)**

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>February 28, 2009</b>	<b>February 29, 2008</b>	<b>February 28, 2009</b>	<b>February 29, 2008</b>
Net sales	\$ 49,447	\$ 40,725	\$ 142,234	\$ 119,748
Cost of sales	19,225	15,407	54,862	46,474
<b>Gross profit</b>	<b>30,222</b>	<b>25,318</b>	<b>87,372</b>	<b>73,274</b>
Operating expenses				
Research and development	4,692	3,955	13,079	10,360
Sales and marketing	13,651	11,725	40,735	33,540
General and administrative	6,926	3,409	15,400	11,604
Amortization of intangibles	2,323	1,777	6,816	5,006
Gain on litigation settlement		(3,151)		(3,151)
<b>Total operating expenses</b>	<b>27,592</b>	<b>17,715</b>	<b>76,030</b>	<b>57,359</b>
<b>Operating income</b>	<b>2,630</b>	<b>7,603</b>	<b>11,342</b>	<b>15,915</b>
Other income (expenses)				
Interest income	415	866	1,291	2,602
Interest expense	(193)	(364)	(552)	(1,105)
Other expense, net	(129)	(264)	(1,397)	(809)
<b>Total other income (expenses)</b>	<b>93</b>	<b>238</b>	<b>(658)</b>	<b>688</b>
<b>Income before income tax provision</b>	<b>2,723</b>	<b>7,841</b>	<b>10,684</b>	<b>16,603</b>
Income tax provision	811	2,951	3,654	6,233
<b>Net income</b>	<b>\$ 1,912</b>	<b>\$ 4,890</b>	<b>\$ 7,030</b>	<b>\$ 10,370</b>
Earnings per common share				
Basic	\$ 0.08	\$ 0.20	\$ 0.29	\$ 0.43
Diluted	\$ 0.08	\$ 0.20	\$ 0.29	\$ 0.43

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY AND COMPREHENSIVE INCOME****Nine Months Ended February 28, 2009****(unaudited)****(in thousands, except share data)**

	Common Stock		Additional paid in capital	Retained earnings	Accumulated other comprehensive loss	Total	Comprehensive income
	Shares	Amount					
Balance at May 31, 2008	24,268,266	\$ 243	\$ 350,598	\$ 4,908	\$ (36)	\$ 355,713	
Net income				7,030		7,030	\$ 7,030
Exercise of stock options	61,414	2	672			674	
Tax benefit on exercise of stock options and issuance of performance shares	3,501		(104)			(104)	
Purchase of common stock under Employee Stock Purchase Plan	92,937		1,091			1,091	
Stock-based compensation			4,508			4,508	
Unrealized gain on marketable securities, net of tax of \$21					39	39	39
Unrealized loss on interest rate swap, net of tax of \$70					(133)	(133)	(133)
Foreign currency translation					(933)	(933)	(933)
Comprehensive income							\$ 6,003
Balance at February 28, 2009	24,426,118	\$ 245	\$ 356,765	\$ 11,938	\$ (1,063)	\$ 367,885	

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****CONSOLIDATED STATEMENTS OF CASH FLOWS****(unaudited)****(in thousands)**

	<b>Nine months Ended</b>	
	<b>February 28, 2009</b>	<b>February 29, 2008</b>
<b>Cash flows from operating activities:</b>		
Net income	\$ 7,030	\$ 10,370
<b>Adjustments to reconcile net income to net cash provided by operating activities:</b>		
Depreciation and amortization	8,814	6,689
Amortization of bond discount	59	(327)
Tax effect on exercise of stock options and issuance of performance shares	(104)	223
Deferred income taxes	2,438	4,901
Write offs of excess and obsolete inventory	587	671
Stock based compensation	4,508	3,658
Imputed interest	189	
Provision for doubtful accounts		217
Other	77	41
<b>Changes in operating assets and liabilities:</b>		
Accounts receivable	1,198	(2,242)
Inventories	(6,444)	1,881
Prepaid expenses and other	674	(2,009)
Accounts payable and accrued liabilities	1,704	(509)
Litigation provision	(6,757)	(3,151)
Other long term liabilities		361
Income taxes payable	(933)	(642)
<b>Net cash provided by operating activities</b>	<b>13,040</b>	<b>20,132</b>
<b>Cash flows from investing activities:</b>		
Additions to property, plant and equipment	(3,472)	(4,792)
Acquisition of intangible assets and business	(17,078)	(3,471)
Change in restricted cash	68	(9,195)
Purchases of marketable securities	(24,295)	(35,700)
Proceeds from sale or maturity of marketable securities	34,811	45,350
<b>Net cash used in investing activities</b>	<b>(9,966)</b>	<b>(7,808)</b>
<b>Cash flows from financing activities:</b>		
Repayment of long-term debt and convertible notes	(9,955)	(230)
Proceeds from exercise of stock options and ESPP	1,765	3,209
Tax benefit on the exercise of stock options and issuance of performance shares		30
<b>Net cash (used in) provided by financing activities</b>	<b>(8,190)</b>	<b>3,009</b>
Effect of exchange rate changes on cash and cash equivalents	(148)	
<b>Decrease in cash and cash equivalents</b>	<b>(5,264)</b>	<b>15,333</b>
Cash and cash equivalents		



Edgar Filing: ANGIODYNAMICS INC - Form 10-Q

Beginning of period	32,040	28,313
End of period	\$ 26,776	\$ 43,646

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**February 28, 2009 and February 29, 2008**

**(unaudited)**

**NOTE A CONSOLIDATED FINANCIAL STATEMENTS**

The consolidated balance sheet as of February 28, 2009, the consolidated statement of stockholders' equity and comprehensive income for the nine months ended February 28, 2009, the consolidated statements of income for the three and nine months ended February 28, 2009 and February 29, 2008, and the consolidated statements of cash flows for the nine months ended February 28, 2009 and February 29, 2008 have been prepared by the Company without audit. The consolidated balance sheet as of May 31, 2008 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (which include only normally recurring adjustments) necessary to state fairly the financial position, changes in stockholders' equity and comprehensive income, results of operations and cash flows as of and for the period ended February 28, 2009 (and for all periods presented) have been made.

Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended May 31, 2008, filed by the Company on August 14, 2008. The results of operations for the periods ended February 28, 2009 and February 29, 2008 are not necessarily indicative of the operating results for the respective full fiscal years.

The unaudited interim consolidated financial statements for the three and nine months ended February 28, 2009 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, Leacor, Inc. ( Leacor ), RITA Medical Systems, LLC, and Oncobionic, Inc. since May 9, 2008, and AngioDynamics UK Limited since June 17, 2008 (collectively, the Company ). All intercompany balances and transactions have been eliminated.

Historically, the Company reported its results of operations as a single segment. Beginning with fiscal 2009, the Company organized its business into three reportable segments: Peripheral Vascular, Access and Oncology/Surgery. The Peripheral Vascular segment is comprised of the venous, angiographic, PTA, drainage and thrombolytic product lines. The Access segment is comprised of the dialysis, ports and PICC product lines. The Oncology/Surgery segment is comprised of the RFA, embolization, Habib and NanoKnife product lines. Note J, Segment and Geographic Information, of these consolidated financial statements reflects the Company's revenues, gross profit and operating income for these segments. The three and nine month information for the prior year has been adjusted to reflect these new business segments for revenue and gross profit. The Company did not disclose operating income by segment for the prior periods because it was impracticable to do so.

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**February 28, 2009 and February 29, 2008**

**(unaudited)**

**NOTE B ACQUISITIONS**

***FlowMedica, Inc.***

On January 12, 2009 the Company completed the acquisition of certain assets of FlowMedica, Inc. for approximately \$1.75 million in cash and a contingent payment based on fiscal 2011 sales of FlowMedica products. With this acquisition, the Company purchased the Benephit product line, a therapeutic approach to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injury, in the emerging field of Targeted Renal Therapy. Intangible assets acquired totaled approximately \$1.3 million which have been identified as product technologies (13-year weighted average useful life.) Inventory acquired totaled approximately \$400,000. The acquisition is being accounted for as a purchase and accordingly, the Company has included the results of operations in the financial statements effective January 12, 2009. The pro-forma effects of the acquisition were not material to the Company's income statement and balance sheet. Ten employees of FlowMedica, Inc. became employees of the Company upon completion of the acquisition.

***Diomed, Inc. and Diomed UK Limited.***

On June 17, 2008, the Company completed the acquisition of certain U.S. assets of Diomed, Inc. and UK assets of Diomed UK Limited, in separate transactions, for an aggregate purchase price of approximately \$11.1 million in cash including capitalized acquisition costs. With this acquisition, the Company substantially strengthened its position in the market for the treatment of varicose veins. The combination of Diomed endovenous laser products with the Company's existing venous product line provides the Company with a comprehensive venous product offering. The total of the net assets acquired was \$5.5 million.

Goodwill recorded as a result of these acquisitions was approximately \$1.9 million. Intangibles assets acquired, other than goodwill, totaled approximately \$3.7 million of which \$3.6 million has been identified as customer relationships (8 -year estimated weighted average useful life) and \$100,000 has been identified as product technologies (10 -year estimated weighted average useful life).

The acquisition has been accounted for as a purchase and, accordingly, the Company has included the results of operations in the financial statements effective June 17, 2008. The pro-forma effects of the Diomed acquisition on the Company's income statement and balance sheet were not material. Thirty five employees of Diomed became employees of the Company upon completion of the acquisitions.

***Oncobionic, Inc.***

On May 9, 2008, the Company completed the acquisition of all the issued and outstanding shares of capital stock of Oncobionic, Inc. pursuant to the terms of the Stock Purchase Agreement entered into on October 12, 2006. The closing of the acquisition comes as a result of the successful use of irreversible electroporation (IRE) technology in the first human clinical trial for the treatment of soft tissue, conducted during the first week of April 2008.

---

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**February 28, 2009 and February 29, 2008**

**(unaudited)**

**NOTE B ACQUISITIONS (cont d)**

Under the October 2006 Stock Purchase Agreement, the Company agreed to pay a total purchase price of \$25.4 million, including \$400,000 of assumed liabilities. The Company made payments of \$5.0 million upon the execution of the stock purchase agreement in October 2006, \$10.0 million on May 9, 2008 upon the closing of the acquisition and \$5.0 million in November 2008. The remaining \$5.0 million is payable in November 2009 and included on the balance sheet under the caption Other current liabilities, net of discount as of February 28, 2009.

The Stock Purchase Agreement also provides for future royalty payments due on net sales of any catheter-based products sold by the Company that incorporate irreversible electroporation technology ( IRE ). The Company holds a license to such technology under a license agreement with the Regents of the University of California (the UC License ).

The Company has accounted for the acquisition of Oncobionic as a purchase under accounting principles generally accepted in the United States of America. Under the purchase method of accounting, the assets and liabilities of Oncobionic were recorded as of the acquisition date, at their respective fair values, and consolidated with those of AngioDynamics. \$25.2 million of the purchase price was recorded as product technology and is being amortized over a 15 year useful life. The Company has recorded goodwill and a deferred tax liability of \$9.3 million. In future periods the deferred tax liability will be reduced to offset the tax impact of non-deductible amortization expense on the intangible assets acquired. The pro-forma impact on prior year results of operations for the nine month period would be approximately \$1,260,000 of additional amortization expense or \$780,000, net of tax.

**NOTE C ASSET PURCHASE AGREEMENTS**

***Medron, Inc.***

On May 1, 2006, the Company entered into an Asset Purchase Agreement (the Agreement ) with Medron, Inc. to acquire the rights, titles, and interests in, and to, Patent Pending Technology for purposes of manufacturing, marketing, and selling proprietary Vascular Access Ports, following administrative approval. As of February 28, 2009, the Company has paid \$5.5 million in accordance with the Agreement. That amount, net of accumulated amortization, has been included on the balance sheet under the caption Intangible assets and is being amortized on a straight line basis over the expected useful life of the assets. A potential future payment of \$2.5 million is due upon issuance (within 10 years of the effective date of the Agreement) of a U.S. patent claiming priority to the Patent Application, or any issuance of a patent to the Company within 10 years of the effective date of the Agreement in which the original owners are the inventors.

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****February 28, 2009 and February 29, 2008****(unaudited)****NOTE D INVENTORIES, net**

	February 28, 2009	May 31, 2008
	(in thousands)	
Raw materials	\$ 12,740	\$ 10,383
Work in process	3,328	3,565
Finished goods	19,743	12,647
Gross Inventories	35,811	26,595
Less: Reserves	(3,396)	(3,694)
Inventories, net	\$ 32,415	\$ 22,901

**NOTE E GOODWILL AND INTANGIBLE ASSETS**

Goodwill is not amortized but rather is tested for impairment during the third quarter of each fiscal year or more frequently if impairment indicators arise. As a result of the test performed in the third quarter of 2009, no impairment provision was required. Intangible assets with determinable useful lives are amortized over their useful lives. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values at the date of acquisition.

Changes in the carrying amount of goodwill for the nine months ended February 28, 2009 are as follows (in thousands):

Balance, May 31, 2008	\$ 162,707
Goodwill recorded as part of the Diomed, Inc. acquisition	1,870
Adjustments to purchase price allocation	(2,587)
Balance, February 28, 2009	\$ 161,990

During the nine months ended February 28, 2009, the Company benefitted from the tax deduction of costs incurred related to the acquisition of Rita Medical Systems, Inc. These deductions resulted in a decrease in taxes payable and an increase in the acquired deferred tax asset and thereby reduced the recorded value of goodwill. This change is reflected above as an adjustment to purchase price allocation.

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**February 28, 2009 and February 29, 2008**

**(unaudited)**

**NOTE E GOODWILL AND INTANGIBLE ASSETS (cont d)**

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Beginning in fiscal 2009 the Company began reporting three operating segments. The Company's reporting units are consistent with the Company's operating segments, and include Peripheral Vascular, Access and Oncology/Surgery. As a result, the carrying value of goodwill was allocated to each of the Company's reporting units on a relative fair value basis. The Company completed its annual evaluation of goodwill by reporting unit as of December 31, 2008. The Company's assessment of goodwill impairment indicated that the fair value of each of the Company's reporting units exceeded its carrying value and therefore goodwill in each of the reporting units was not impaired. The fair value of Peripheral Vascular, Access and Oncology/Surgery exceeded its carrying value by 29%, 5% and 3%, respectively. The sum of the fair values of the reporting units was reconciled to the Company's current market capitalization (based upon the Company's stock price) plus an estimated control premium of approximately 19% as of December 31, 2008.

To determine fair value, the Company utilized two market-based approaches and an income approach. Under the market-based approaches, the Company utilized information regarding the Company as well as publicly available industry information to determine earnings multiples and sales multiples. Under the income approach, the Company determined fair value based on estimated future cash flows of each reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. The Company determined the discounted cash flow as the best indicator to determine fair value.

Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. Solely for purposes of establishing inputs for the fair value calculations, the Company assumed that the current economic conditions would continue through fiscal year 2010, followed by a recovery period in fiscal years 2011 and 2012. In addition, the Company applied gross margin assumptions consistent with the Company's historical trends at various revenue levels and used a EBITDA exit multiple of 6.5, 7.0 and 8.0 to calculate the terminal value of the Peripheral Vascular, Access and Oncology/Surgery reporting units, respectively, compared to an EBITDA exit multiple of 8.0 used in the prior year. In addition, the Company used a discount rate of 19%, 16% and 19% to calculate the fair value of its Peripheral Vascular, Access and Oncology/Surgery reporting units, respectively. This discount rate is higher than the 14% discount rate used in the prior year, primarily due to the fact that additional risk premiums were added to take into account the economic downturn and specific inherent risks associated with each reporting unit.

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**February 28, 2009 and February 29, 2008**

**(unaudited)**

**NOTE E GOODWILL AND INTANGIBLE ASSETS (cont d)**

Since early November 2008, our stock market capitalization has generally been lower than our shareholders' equity or book value. However, our reporting units have continued to generate significant cash flow from their operations, and we expect that they will continue to do so in 2009 and beyond. Furthermore, given the relatively small difference between our stock price and our book value per share, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our trading prices and our book value.

Even though the Company determined that there was no goodwill impairment as of December 31, 2008, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal factors or business climate, an adverse action or assessment by a regulator, unanticipated competition, a material negative change in relationships with significant customers, strategic decisions made in response to economic or competitive conditions, loss of key personnel or a more-likely-than-not expectation that a reporting unit or a significant portion of a reporting unit will be sold or disposed of, would require an interim assessment for some or all of the reporting units prior to the next required annual assessment on December 31, 2009. It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material.

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****February 28, 2009 and February 29, 2008****(unaudited)****NOTE E GOODWILL AND INTANGIBLE ASSETS (cont d)**

Intangible assets are amortized over their estimated useful lives. The balances of intangible assets are as follows:

	Gross carrying value	February 28, 2009 Accumulated amortization (in thousands)	February 28, 2009 Net carrying value	Weighted avg useful life (years)
Product technologies	\$ 48,648	\$ (7,331)	\$ 41,317	13.2
Customer relationships	31,125	(8,033)	23,092	6.6
Licenses	6,040	(1,134)	4,906	9.1
Distributor relationships	900	(625)	275	3.0
Trademarks	600	(125)	475	10.0
	\$ 87,313	\$ (17,248)	\$ 70,065	

	Gross carrying value	May 31, 2008 Accumulated amortization (in thousands)	May 31, 2008 Net carrying value	Weighted avg useful life (years)
Product technologies	\$ 47,203	\$ (4,330)	\$ 42,873	13.6
Customer relationships	27,500	(4,924)	22,576	7.5
Licenses	5,540	(698)	4,842	9.9
Distributor relationships	900	(400)	500	3.0
Trademarks	600	(80)	520	10.0
	\$ 81,743	\$ (10,432)	\$ 71,311	

**NOTE F ACCRUED LIABILITIES**

Accrued liabilities consist of the following:

	February 28, 2009	May 31, 2008
Payroll and related expenses	\$ 5,532	\$ 5,051
Sales and franchise taxes	1,041	1,112
Royalties	1,048	763
Fair value of interest rate swap	1,039	416
Other	1,839	2,181



Edgar Filing: ANGIODYNAMICS INC - Form 10-Q

Total

\$ 10,499 \$ 9,523

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****February 28, 2009 and February 29, 2008****(unaudited)****NOTE G CEO TRANSITION COSTS**

On January 20, 2009, the Company entered into an Employment Agreement and Non-Statutory Stock Option Agreement with its chief executive officer that provided, among other things, for a transition to a new chief executive officer ( CEO transition ). The transition to the new chief executive was completed in the three month period ended February 28, 2009 and the former chief executive officer is not expected to have an operating role with the Company after March 1, 2009. Accordingly, the Company recorded a provision in the fiscal third quarter of approximately \$2.8 million in its general and administrative expenses for all current and future costs associated with the aforementioned Employment Agreement and Non-Statutory Stock Option Agreement and certain costs associated with the recruitment of its new chief executive officer. At February 28, 2009, approximately \$1.6 million of related CEO transition costs was included in accrued liabilities.

**NOTE H INCOME TAXES**

The Company's effective income tax rate for the three month periods ending February 28, 2009 and February 29, 2008 was 29.8% and 37.6%, respectively. The Company's effective income tax rate for the nine month periods ending February 28, 2009 and February 29, 2008 was 34.2% and 37.5%, respectively. Both the current quarter and the nine month period ending February 28, 2009 benefitted from reenactment of legislation surrounding research and development tax credits.

**NOTE I EARNINGS PER COMMON SHARE**

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share further includes the dilutive effect of potential common stock consisting of stock options, warrants, and restricted stock units, provided that the inclusion of such securities is not antidilutive.

The following table sets forth the reconciliation of the weighted-average number of common shares:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>February</b>	<b>February</b>	<b>February</b>	<b>February</b>
	<b>28,</b>	<b>29,</b>	<b>28,</b>	<b>29,</b>
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Basic	24,365,757	24,122,744	24,341,792	24,042,214
Effect of dilutive securities	118,384	280,788	159,106	300,349
Diluted	24,484,141	24,403,532	24,500,898	24,342,563

Excluded from the calculation of diluted earnings per common share, are options and warrants issued to employees and non-employees to purchase 1,501,025 and 1,384,362 shares of common stock for the three and

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****February 28, 2009 and February 29, 2008****(unaudited)****NOTE I EARNINGS PER COMMON SHARE (cont d)**

nine months ended February 28, 2009 and 1,954,509 and 1,984,043 for the three and nine months ended February 29, 2008, respectively as their inclusion would be antidilutive. The exercise prices of these options were between \$11.93 and \$93.52 at February 28, 2009. For the three and nine months ended February 29, 2008, shares issuable upon conversion of a convertible note into 414,476 shares of common stock, with a conversion price of \$20.41, were excluded from the calculation of diluted earnings per share, as their inclusion would have been antidilutive. On August 1, 2008, the convertible note matured and was paid off in cash.

**NOTE J SEGMENT AND GEOGRAPHIC INFORMATION**

Historically, the Company reported its results of operations as a single segment. Beginning with fiscal 2009, the Company has organized its business into three reportable segments: Peripheral Vascular, Access and Oncology/Surgery. The Peripheral Vascular segment is comprised of the venous, angiographic, PTA, drainage and thrombolytic product lines. The Access segment is comprised of the dialysis, ports and PICC product lines. The Oncology/Surgery segment is comprised of the RFA, embolization, Habib and NanoKnife product lines.

Selected information by reportable segment is presented in the following tables (in thousands):

	Three Months Ended		Nine Months Ended	
	February 28, 2009	February 29, 2008	February 28, 2009	February 29, 2008
Net sales				
Peripheral Vascular	\$ 20,743	\$ 15,411	\$ 60,947	\$ 45,884
Access	17,176	15,846	48,931	46,322
Oncology/Surgery	11,528	9,468	32,356	27,542
<b>Total</b>	<b>\$ 49,447</b>	<b>\$ 40,725</b>	<b>\$ 142,234</b>	<b>\$ 119,748</b>
Gross profit				
Peripheral Vascular	\$ 12,322	\$ 8,892	\$ 35,181	\$ 25,647
Access	10,186	9,512	29,609	27,526
Oncology/Surgery	7,714	6,914	22,582	20,101
<b>Total</b>	<b>\$ 30,222</b>	<b>\$ 25,318</b>	<b>\$ 87,372</b>	<b>\$ 73,274</b>
Operating income(expense)				
Peripheral Vascular	\$ 2,226		\$ 8,171	
Access	2,134		6,981	
Oncology/Surgery	(1,730)		(3,810)	
<b>Total</b>	<b>\$ 2,630</b>		<b>\$ 11,342</b>	

The first three and nine months of fiscal 2008 have been presented to reflect these new reportable segments for net sales and gross profit. Operating income for the prior periods has not been disclosed as it was impracticable to do so.



**Table of Contents****AngioDynamics, Inc. and Subsidiaries****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****February 28, 2009 and February 29, 2008****(unaudited)****NOTE J SEGMENT AND GEOGRAPHIC INFORMATION (cont d)**

In accordance with FAS No. 131, Disclosures About Segments of an Enterprise and Related Information, the internal organization that is used by management for making operating decisions and assessing performance is used as the source of the Company's reportable segments. The accounting policies of the segments are the same as those described in Accounting Policies, Note 1, of the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2008, filed by the Company on August 14, 2008. The Company's chief operating decision maker evaluates performance based on the reportable segments and utilizes net sales, gross profit and operating income as primary profitability measures. The expenses related to certain shared and corporate activities are allocated to these segments on a percentage of total sales basis or a percentage of operating expense basis as deemed appropriate.

Total sales for geographic areas are summarized below (in thousands):

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>February 28,</b>	<b>February 29,</b>	<b>February 28,</b>	<b>February 29,</b>
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
<b>Net Sales by Geography</b>				
United States	\$ 44,074	\$ 37,021	\$ 126,262	\$ 108,617
International	5,373	3,704	15,972	11,131
<b>Total</b>	<b>\$ 49,447</b>	<b>\$ 40,725</b>	<b>\$ 142,234</b>	<b>\$ 119,748</b>

**NOTE K FAIR VALUE**

Effective June 1, 2008, the Company adopted SFAS No. 157, Fair Value Measurements (SFAS 157). SFAS 157 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. Fair value is defined under SFAS 157 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. SFAS 157 establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value which are provided in the table below. The adoption of SFAS 157 had no impact on the Company's financial statements other than the disclosures presented herein. There were no changes in the level 3 fair value instruments for the nine months ended February 28, 2009.

**Table of Contents****AngioDynamics, Inc. and Subsidiaries****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****February 28, 2009 and February 29, 2008****(unaudited)****NOTE K FAIR VALUE (cont d)**

	Fair Value Measurements at February 28, 2009 using (in thousands)				Assets at Fair Value
	Quoted Prices in Active Markets for Identical Assets Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3		
<b>Financial Assets</b>					
Cash equivalents	\$ 12,894	\$ 2,997	\$		\$ 15,891
Marketable securities		33,707	1,850		35,557
Total Financial Assets	\$ 12,894	\$ 36,704	\$ 1,850		\$ 51,448
<b>Financial Liabilities</b>					
Interest rate swap agreements	\$	\$ 1,039	\$		\$ 1,039
Total Financial Liabilities	\$	\$ 1,039	\$		\$ 1,039

In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities, which allows an entity to elect to record financial assets and financial liabilities at fair value upon their initial recognition on a contract-by-contract basis. The Company did not adopt Statement No. 159.

**NOTE L LITIGATION**

In April 2008, the Company entered into a settlement with Diomed for the purpose of resolving litigation alleging patent infringement litigation. As a result of the settlement, the Company reduced its litigation provision and recorded a gain of approximately \$3.2 million as reflected under the income statement caption Gain on litigation settlement for the three and nine months ended February 29, 2008.

The Company is party to legal actions that arise in the ordinary course of business. The Company believes that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**February 28, 2009 and February 29, 2008**

**(unaudited)**

**NOTE M RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS**

In November 2007, the Emerging Issues Task Force (EITF) reached a consensus on EITF Issue No. 07-01, Accounting for Collaborative Arrangements (EITF No. 07-01). EITF No. 07-01 establishes disclosure requirements for arrangements entered into by companies to collaboratively develop, manufacture, or market products. EITF No. 07-01 also establishes income statement classification of collaboration transactions between the parties. EITF No. 07-01 is effective for fiscal years beginning after December 15, 2008 (the Company's 2010 fiscal year). The Company is currently evaluating the impact this adoption will have on the Company's consolidated financial statements.

In December 2007, FASB issued Statement of Financial Accounting Standards No. 141(R), Business Combinations (SFAS 141(R)). SFAS 141(R) establishes principles and requirements for how the acquirer in a business combination recognizes and measures the assets acquired, liabilities assumed and any noncontrolling interest in the acquiree; recognizes and measures the goodwill acquired or gain from a bargain purchase; and determines what information to disclose to enable readers of the financial statements to evaluate the nature and financial effects of the business combination. SFAS 141(R) is effective for business combinations for which the acquisition date is on or after fiscal years beginning after December 15, 2008 (the Company's 2010 fiscal year) and will be applied prospectively. The adoption of this pronouncement is not expected to have a material impact on the Company's financial statements.

In December 2007, FASB issued Statement of Financial Accounting Standards No. 160, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51 (SFAS 160). SFAS 160 establishes accounting and reporting standards that require companies to more clearly identify in the financial statements and disclose the impact of noncontrolling interest in a consolidated subsidiary on the consolidated financial statements. SFAS 160 is effective for fiscal years beginning after December 15, 2008 (the Company's 2010 fiscal year), and interim periods within those fiscal years. The adoption of this pronouncement is not expected to have a material impact on the Company's financial statements.

In March 2008, FASB issued Statement of Financial Accounting Standards No. 161, Disclosures about Derivative Instruments and Hedging Activities (SFAS 161). SFAS 161 is intended to improve financial reporting about derivative instruments and hedging activities by requiring companies to enhance disclosure about how these instruments and activities affect their financial position, performance and cash flows. SFAS 161 also improves the transparency about the location and amounts of derivative instruments in a company's financial statements and how they are accounted for under SFAS 133. SFAS 161 is effective for financial statements issued for fiscal years beginning after November 15, 2008 (the Company's 2010 fiscal year), and interim periods within, beginning after that date. The Company is currently evaluating the impact this adoption will have on the Company's consolidated financial statements.

## **Table of Contents**

### **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

#### **Forward-Looking Statements**

This quarterly report on Form 10-Q, including the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations", contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the ability of the Company to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in the Company's reports filed with the SEC, including the Company's Form 10-K for the fiscal year ended May 31, 2008.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

#### **Overview**

AngioDynamics is a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease, or PVD, and local oncology therapy options for treating cancer, including radiofrequency ablation (RFA) systems, irreversible electroporation (IRE) surgical resection systems and embolization products for treating benign and malignant tumors. We design, develop, manufacture and market a broad line of therapeutic and diagnostic devices that enable interventional physicians (interventional radiologists, vascular surgeons, interventional and surgical oncologists and others) to treat PVD, tumors, and other non-coronary diseases. For the past five fiscal years, over 95% of our net sales were from single-use, disposable products.

Historically, we reported our results of operations as a single segment. Beginning with fiscal 2009, we have organized our business into three reportable segments: Peripheral Vascular, Access and Oncology/Surgery. The Peripheral Vascular segment is comprised of the venous, angiographic, PTA, drainage and thrombolytic product lines. The Access segment is comprised of the dialysis, ports and PICC product lines. The Oncology/Surgery segment is comprised of the RFA, embolization, Habib and NanoKnife product lines. Prior periods have been recast for net sales and gross profit for this new reporting structure.



## **Table of Contents**

We sell our broad line of quality devices in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. As of February 28, 2009, our sales organization numbered 132 in the U.S. and 15 outside the U.S. For the three and nine months ended February 28, 2009, approximately 11% of our net sales were from non US markets, compared with approximately 9% in the same periods of the prior year.

Our growth depends in large part on the continuous introduction of new and innovative products, together with ongoing enhancements to our existing products, through internal product development, technology licensing and strategic alliances. For each of the past three fiscal years, we invested at least 7% of our net sales in research and development ( R&D ). R&D expenditures were approximately 9% of net sales for the three and nine months ended February 28, 2009. We expect that our R&D expenditures will be approximately 9% of net sales for fiscal 2009 primarily due to investment in IRE technology. We expect R&D expenditures thereafter to continue to be in the range of 9% of net sales due to continued investment in IRE technology and other technology. However, downturns in our business could cause us to reduce our R&D spending.

We are also seeking to grow through selective acquisitions of complementary businesses and technologies. In January 2007, we completed the acquisition of RITA Medical Systems, Inc. This acquisition created a diversified medical technology company with a broad line of access, diagnostic and therapeutic products that enable interventional physicians and surgeons to treat peripheral vascular disease and cancerous tumors. Interventional oncology is a large and growing area for our existing customer base and RITA's leadership position, premium products and excellent reputation fit our strategy. RITA had a very strong position in vascular access ports, which are an ideal sales fit with our Morpheus<sup>®</sup> CT PICC and the vascular access port technology we purchased from Medron in May 2006. In addition, in May 2008 we acquired irreversible electroporation (IRE) technology which will be complementary to RITA's diverse offering of local oncology therapies, including its market-leading RFA systems, Habib Sealer<sup>™</sup> resection devices and LC Beads<sup>™</sup> for tumor embolization. We are in the process of commercializing the IRE technology and recently introduced the NanoKnife generator. In June 2008, we completed the acquisition of certain U.S. and U.K. assets of Diomed, Inc. With this acquisition, we substantially strengthened our position in the market for the treatment of varicose veins. The combination of Diomed endovenous laser products with our existing venous product line provides us with a comprehensive venous product offering. In January 2009, we completed the acquisition of certain assets of FlowMedica, Inc. providing us with the Benephit product line, a therapeutic approach to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injury, in the emerging field of Targeted Renal Therapy.

Except to the extent we can further use our cash and short term investments or our equity securities as acquisition capital, we will require additional equity or debt financing to fund any future significant acquisitions.

In recent years, we expanded our manufacturing and warehousing facilities in Queensbury, New York, to provide us with significantly greater manufacturing and warehousing capacity and to accommodate additional research, development and administrative requirements. We are not currently operating our manufacturing facilities at full capacity. However, we anticipate requiring additional office space for additional engineering, marketing and administrative personnel in the near future.

Our ability to further increase our profitability will depend in part on improving gross profit margins. Factors such as changes in our product mix, new technologies and unforeseen price pressures may cause our margins to grow at a slower rate than we have anticipated, or to decline.

## **Table of Contents**

### **Recent Developments**

#### *Acquisition of FlowMedica, Inc.*

On January 12, 2009 we completed the acquisition of certain assets of FlowMedica, Inc. for approximately \$1.75 million in cash and a contingent payment based on fiscal 2011 sales of FlowMedica products. With this acquisition, we purchased the Benephit product line, a therapeutic approach to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injury, in the emerging field of Targeted Renal Therapy. Intangible assets acquired totaled approximately \$1.3 million which have been identified as product technologies (13-year weighted average useful life.) Inventory acquired totaled approximately \$400,000. The acquisition is being accounted for as a purchase and accordingly, we have included the results of operations in the financial statements effective January 12, 2009. The pro-forma effects of the acquisition were not material to our income statement and balance sheet. Ten employees of FlowMedica, Inc. became employees upon completion of the acquisition.

#### *Acquisition of certain assets of Diomed*

On June 17, 2008, we completed the acquisition of certain U.S. assets of Diomed, Inc. and UK assets of Diomed UK Limited., in separate transactions, for an aggregate purchase price of approximately \$11.1 million in cash including capitalized acquisition costs. With this acquisition, we substantially strengthened our position in the market for the treatment of varicose veins. The combination of Diomed endovenous laser products with our existing venous product line provides us with a comprehensive venous product offering. The total of the net tangible assets acquired was \$5.5 million. Goodwill recorded as a result of these acquisitions was approximately \$1.9 million. Intangibles assets acquired, other than goodwill, totaled approximately \$3.7 million of which \$3.6 million has been identified as customer relationships (8 -year estimated weighted average useful life) and \$100,000 has been identified as product technologies (10 -year estimated weighted average useful life).

The acquisition is being accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective June 17, 2008. The pro-forma effects of the Diomed acquisition on our income statement and balance sheet were not material. Thirty five employees of Diomed became employees of ours upon completion of the acquisition.

#### *Acquisition of Oncobionic, Inc.*

On May 9, 2008, we completed the acquisition of all the issued and outstanding shares of capital stock of Oncobionic, Inc. pursuant to the terms of the Stock Purchase Agreement entered into on October 12, 2006. The closing of the acquisition comes as a result of the successful use of irreversible electroporation (IRE) technology in the first human clinical trial for the treatment of soft tissue, conducted during the first week of April 2008.

Under the October 2006 Stock Purchase Agreement, we agreed to pay a total purchase price of \$25.4 million, including \$400,000 of assumed liabilities. We made payments of \$5.0 million upon the execution of the stock purchase agreement in October 2006, \$10.0 million on May 9, 2008 upon the closing of the acquisition, and \$5.0 million in November 2008. The remaining \$5.0 million is payable in November 2009.

The Stock Purchase Agreement also provides for future royalty payments due on net sales of any catheter-based products sold by us that incorporate irreversible electroporation technology ( IRE ). We hold a license to such technology under a license agreement with the Regents of the University of California (the UC License ).

**Table of Contents**

We have accounted for the acquisition of Oncobionic as a purchase under accounting principles generally accepted in the United States of America. Under the purchase method of accounting, the assets and liabilities of Oncobionic were recorded as of the acquisition date, at their respective fair values, and consolidated with those of AngioDynamics. Substantially all of the purchase price was recorded as product technology and is being amortized over a 15 year useful life. We have recorded goodwill and a deferred tax liability of \$9.3 million. In future periods the deferred tax liability will be reduced to offset the tax impact of non-deductible amortization expense on the intangible assets acquired. The pro-forma impact on prior year results of operations for the nine month period would be approximately \$1,260,000 of additional amortization expense or \$780,000, net of tax.

**Results of Operations****Three Months ended February 28, 2009 and February 29, 2008**

**Financial Summary.** For the third quarter of fiscal 2009, we reported net income of \$1.9 million, or \$0.08 per diluted common share, on net sales of \$49.4 million, compared with net income of \$4.9 million, or \$0.20 per diluted common share, on net sales of \$40.7 million in the third quarter of the prior year. Gross profit was 61.1% in the third quarter of fiscal 2009 compared with 62.2% in the third quarter of the prior year.

The following table sets forth certain operating data as a percentage of net sales:

	<b>Three Months Ended</b>	
	<b>February 28, 2009</b>	<b>February 29, 2008</b>
Net sales	100.0%	100.0%
Gross profit	61.1%	62.2%
Research and development expenses	9.5%	9.7%
Sales and marketing expenses	27.6%	28.8%
General and administrative expenses	14.0%	8.4%
Amortization of intangibles	4.7%	4.4%
Gain on litigation settlement	0.0%	-7.7%
Operating income	5.3%	18.7%
Other income(expenses)	0.2%	0.6%
Net income	3.9%	12.0%

**Net sales.** Net sales for the fiscal third quarter of 2009 increased by 21%, or \$8.7 million, to \$49.4 million, from \$40.7 million in the fiscal third quarter of 2008. \$5.2 million of the \$8.7 million was attributable to increased sales of laser ablation products, including those acquired from Diomed. The balance of the growth in net sales was primarily attributable to increased unit sales of LC Bead and the SmartPort CT.

From a business unit perspective, Peripheral Vascular sales increased 35% to \$20.7 million from \$15.4 million. \$5.2 million of the increase was attributable to increased sales of laser ablation products, including those acquired from Diomed. Laser ablation sales increased from \$3.1 million in the fiscal third quarter of 2008 to \$8.3 million in the fiscal third quarter of 2009, reflecting the acquisition of Diomed and the integration of the VenaCure EVLT product line. Access sales were \$17.2 million, an increase of 8%, primarily attributable to increased unit sales of SmartPort CT. Oncology/Surgery sales were \$11.5 million, an increase of 22% over the prior year primarily as a result of strong sales of our chemoembolization product, LC Bead.

From a geographical perspective, US sales increased \$7.1 million or 19% in the third quarter of 2009 to \$44.1 million from \$37.0 million a year ago. Approximately \$3.3 million of this increase is attributable to the sales of products acquired from Diomed. The balance of this increase is primarily attributable to increased unit sales of LC Bead and the SmartPort CT. International sales increased \$1.7 million or 45% in the third quarter of 2009 to \$5.4 million from \$3.7 million a year ago. Approximately \$1.9 million of this increase is attributable to the sales of products acquired from Diomed, offset by decreased sales of our RF Ablation devices. IRE products (Nanoknife) contributed \$110,000 in the third quarter of 2009 in International Oncology/Surgery business segment sales.

---

**Table of Contents**

**Gross profit.** Our gross profit as a percentage of sales decreased to 61.1% for the third quarter of 2009 from 62.2% for the same period in the prior year. The decrease in gross profit percentage was primarily due to product mix.

**Research and development expenses.** Research and development ( R&D ) expenses increased by \$737,000, or 19%, to \$4.7 million in the third fiscal quarter of 2009. The increase is primarily due to increased engineering personnel to support IRE development and commercialization activities as \$2.1 million was spent on the program in the third quarter of fiscal 2009. As a percentage of net sales, R&D expenses were 9.5% for the fiscal third quarter of 2009, compared with 9.7% for the same prior year period. At February 28, 2009, we employed 75 people in research, development and regulatory activities compared with 55 people in the prior year quarter.

**Sales and marketing expenses.** Sales and marketing ( S&M ) expenses increased \$1.9 million or 16% to \$13.7 million in the third quarter of fiscal 2009. Sales expenses accounted for \$1.2 million of the increase, which represented a 13% increase over the prior year, due to personnel expenses related to the increased number of sales territories under the program to expand our Peripheral Vascular and Access sales forces with the addition of 19 new sales representatives, personnel hired in the Diomed acquisition and IRE sales activities. Marketing expenses increased approximately \$700,000, or 27%, over the prior year period, primarily due to IRE marketing activities, increased headcount, costs relating to the Diomed acquisition, and additional tradeshows activities. As a percentage of net sales, S&M expenses were 27.6% for the fiscal third quarter of 2009, compared with 28.8% for the prior year period. \$340 thousand was spent on IRE sales and marketing activity in the third quarter of fiscal 2009. At February 28, 2009, we employed 185 people in sales and marketing activities, of whom 13 were added in conjunction with the Diomed acquisition, compared with 153 people in the prior year quarter.

**General and administrative expenses.** General and administrative ( G&A ) expenses increased \$3.5 million, or 100%, to \$6.9 million primarily due to \$2.8 million in transition costs for the CEO position with the remaining due to increased headcount for infrastructure growth across the administrative functions and business unit general management costs, partially offset by reduced legal expenses from now resolved litigation. G&A expenses were 14.0% of net sales, or 8.3% of net sales excluding the CEO transition costs, for the 2009 fiscal third quarter as compared with 8.4% for the prior year third fiscal quarter. As of February 28, 2009, we employed 53 people in general and administrative activities, of whom 5 were added in conjunction with the Diomed acquisition, compared with 36 people in the prior year period.

**Amortization of intangibles.** Amortization of intangibles increased to \$2.3 million in the third quarter of fiscal 2009, from \$1.8 million in the same period of the prior year. The increase is primarily attributable to the amortization of intangibles acquired in the acquisitions of Oncobionic and Diomed. Amortization of IRE intangibles was \$430 thousand in the third quarter of fiscal 2009.

**Gain on litigation settlement.** For the three months ended February 28, 2009, there was no litigation provision (gain on settlement) as compared to the same period of the prior year when the settlement of the Diomed litigation, which occurred on April 2, 2008, provided a gain of \$3.2 million.

**Operating income.** Operating income was \$2.6 million and \$7.6 million for the third quarter of fiscal 2009 and 2008, respectively. As a percentage of sales, operating income for the third quarter of 2009 was 5.3% and would have been 11.0% excluding the aforementioned CEO transition costs, compared with 18.7% in the prior year same period. The prior year period included a \$3.2 million gain related to favorable settlement of outstanding litigation. Without the settlement gain, the prior year period would also have been 10.9% of sales.

**Table of Contents**

**Other income (expenses).** Other income and expenses for the third quarter of fiscal 2009 decreased \$145,000 compared with the same period of the prior year due primarily to decreased interest income on reduced cash balances and lower investment returns as a result of market conditions offset by a gain on an interest rate swap compared with a loss a year ago and lower interest expense as a result of the payment of the Convertible Notes assumed in the acquisition of RITA.

**Income taxes.** Our effective tax rate for the 2009 third fiscal quarter was 29.8% compared to 37.6% a year ago. The current quarter benefited from increased research and development tax credits.

**Net income.** For the third quarter of 2009, we reported net income of \$1.9 million, a decrease of \$3.0 million, from net income of \$4.9 million for the prior year third quarter primarily due to CEO transition costs included in the current period and the inclusion of the gain related to the favorable settlement of outstanding litigation in the prior year period.

**Nine Months ended February 28, 2009 and February 29, 2008**

**Financial Summary.** For the first nine months of fiscal 2009, we reported net income of \$7.0 million, or \$0.29 per diluted common share, on net sales of \$142.2 million, compared with net income of \$10.4 million, or \$0.43 per diluted common share, on net sales of \$119.7 million in the first nine months of the prior year. Gross profit percentage improved to 61.4% for the first nine months of 2009 from 61.2% one year ago.

The following table sets forth certain operating data as a percentage of net sales:

	<b>Nine Months Ended</b>	
	<b>February 28, 2009</b>	<b>February 29, 2008</b>
Net sales	100.0%	100.0%
Gross profit	61.4%	61.2%
Research and development expenses	9.2%	8.7%
Sales and marketing expenses	28.6%	28.0%
General and administrative expenses	10.8%	9.7%
Amortization of intangibles	4.8%	4.2%
Gain on litigation settlement	0.0%	-2.6%
Operating income	8.0%	13.3%
Other income(expenses)	-0.5%	0.6%
Net income	4.9%	8.7%

**Net sales.** Net sales for the fiscal first nine months of 2009 increased by 19%, or \$22.5 million, to \$142.2 million, from \$119.7 million in the fiscal first nine months of 2008. \$14.2 million of the \$22.5 million increase was attributable to increased sales of laser ablation products, including those acquired from Diomed. The balance of the growth in net sales was primarily attributable to increased unit sales of LC Bead, SmartPort CT, the Morpheus insertion kits and Angiographic products.

From a business unit perspective, Peripheral Vascular sales increased 33% to \$60.9 million from \$45.9 million. \$14.2 million of the increase was attributable to increased sales of laser ablation products, including those acquired from Diomed. Laser ablation sales increased from \$9.5 million in the fiscal first nine months of 2008 to \$23.7 million in the fiscal first nine months of 2009, reflecting the acquisition of Diomed and the integration of the VenaCure EVLT product line. Access sales were \$48.9 million, an increase of 6%, primarily attributable to increased unit sales of SmartPort CT and the Morpheus insertion kits. Oncology/Surgery sales were \$32.4 million, an increase of 18% over the prior year, primarily as a result of strong sales of our chemoembolization product, LC Bead.

---

**Table of Contents**

From a geographical perspective, US sales increased \$17.6 million or 16.3% in the first nine months of 2009 to \$126.3 million from \$108.6 million a year ago. Approximately \$9.1 million of this increase is attributable to the sales of products acquired from Diomed. The balance of this increase is primarily attributable to increased unit sales of LC Bead, SmartPort CT, Morpheus insertion kits and Angiographic products. International sales increased \$4.8 million or 43.5% in the first nine months of 2009 to \$15.9 million from \$11.1 million a year ago. This increase is attributable to the sales of products acquired from Diomed, offset by decreased sales of our RF Ablation devices.

**Gross profit.** Our gross profit as a percentage of sales increased to 61.4% for the first nine months of 2009 from 61.2% for the same period in the prior year. The increase in gross profit percentage was attributable to product mix.

**Research and development expenses.** Research and development ( R&D ) expenses increased by \$2.7 million, or 26%, to \$13.1 million in the first nine months of 2009. The increase is primarily due to increased engineering personnel to support IRE development and commercialization activities as \$5.2 million was spent on the program in the first nine months of fiscal 2009. As a percentage of net sales, R&D expenses were 9.2% for the first nine months of fiscal 2009, compared with 8.7% for the same prior year period.

**Sales and marketing expenses.** Sales and marketing ( S&M ) expenses increased \$7.2 million or 22% to \$40.7 million in the first nine months of fiscal 2009. Sales expenses accounted for \$4.8 million of the increase, which represented an 18% increase over the prior year, due to personnel expenses related to the increased number of sales territories under the program to expand our Peripheral Vascular and Access sales forces, personnel hired in the Diomed acquisition and IRE sales activities. Marketing expenses increased \$2.4 million, or 34%, over the prior year period, primarily due to IRE marketing activities, increased headcount, costs related to the Diomed acquisition and additional marketing initiatives as a result of the new business unit strategy. As a percentage of net sales, S&M expenses were 28.6% for the first nine months of 2009, compared with 28.0% for the prior year period. \$780 thousand was spent on IRE sales and marketing activity in the first nine months of fiscal 2009.

**General and administrative expenses.** General and administrative ( G&A ) expenses increased \$3.8 million, or 32.7%, to \$15.4 million for the first nine months of 2009 as compared to the prior year. This increase was primarily due to \$3.0 million of costs associated with the CEO transition. The remaining increase is due to increased headcount for infrastructure growth across the administrative functions and business unit general management costs partially offset by reduced legal expenses from now resolved litigation. G&A expenses were 10.8% of net sales for the 2009 fiscal first nine months, or 8.7% excluding the CEO transition costs, compared with 9.7% for the prior year period.

**Amortization of intangibles.** Amortization of intangibles increased to \$6.8 million in the first nine months of fiscal 2009, from \$5.0 million in the same period of the prior year. The increase is primarily attributable to the amortization of intangibles acquired in the acquisitions of Oncobionic and Diomed. Amortization of IRE intangibles was \$1.3 million in the first nine months of fiscal 2009.

**Gain on litigation settlement.** For the nine months ended February 28, 2009, there was no litigation provision (gain on settlement) compared with the same prior year period when the settlement of the Diomed litigation, which occurred on April 2, 2008, resulted in a gain of \$3.2 million.

**Operating income.** Operating income was \$11.3 million and \$15.9 million for the first nine months of fiscal 2009 and 2008, respectively. As a percentage of sales, operating income for the first nine months of 2009 was 8.0% compared to 13.3% in the prior year same period. Excluding the CEO transition costs, operating income would have been 10.1% for the 2009 period. The prior year period included a \$3.2 million gain related to favorable settlement of outstanding litigation. Without the gain, the prior year period would have been 10.7% of sales.

## **Table of Contents**

**Other income (expenses).** Other income and expenses for the first nine months of fiscal 2009 decreased \$1.3 million compared with the same period of the prior year due primarily to \$1.3 million less interest income on reduced cash balances and lower investment returns as a result of market conditions and \$305,000 of foreign exchange losses. These amounts were offset by lower interest expense as a result of the payment of the Convertible Notes assumed in the acquisition of RITA.

**Income taxes.** Our effective tax rate was 34.2% for the first nine months of 2009 compared with 37.5% a year ago. The current year to date period benefited from R&D tax credit utilization. The R&D tax credit expired on December 31, 2007 and was reinstated on October 3, 2008. The reinstatement retroactively extended R&D tax credits from January 1, 2008 to December 31, 2009. The retroactive impact is reflected in our current year to date tax rate.

**Net income.** For the first nine months of 2009, we reported net income of \$7.0 million, a decrease of \$3.4 million, from net income of \$10.4 million for the prior year period. This decrease is primarily related to CEO transition costs in the current period and the inclusion of the gain related to the favorable settlement of outstanding litigation in the prior year period.

## **Liquidity and Capital Resources**

Our cash, cash equivalents and marketable securities totaled \$62.3 million at February 28, 2009, compared with \$78.3 million at May 31, 2008. Marketable securities are comprised of U.S. government issued or guaranteed securities, corporate bonds and auction rate securities. At February 28, 2009, total debt was \$7.2 million comprised of short and long-term bank debt that financed our facility expansions in Queensbury, New York. This compared with \$17.1 million at May 31, 2008 which also included \$9.7 million of convertible debt assumed in the RITA acquisition which was paid upon maturity in the first quarter of 2009.

Net cash provided by operating activities for the nine months ended February 28, 2009 was \$13.0 million compared with \$20.1 million in the same prior year period. Cash generated from operating activities during the first nine months of fiscal year 2009 was primarily the result of net income and the effect on net income of non cash items, such as depreciation and amortization, stock-based compensation and the provision for deferred income taxes, as well as a decrease in accounts receivable offset by increases in inventories and the \$6.7 million litigation settlement paid to VNUS Medical.

Net cash used in investing activities was \$10.0 million for the nine months ended February 28, 2009 compared with net cash used of \$7.8 million for the same prior year period. The net cash used in fiscal 2009 consisted of \$10.1 million for the acquisition of Diomed assets, \$5.0 million for the contractual Oncobionic payment, \$1.4 million for the acquisition of FlowMedica assets and fixed asset additions of \$3.5 million, offset by net proceeds from the sale, maturity and purchase of available-for-sale short term investments.

Net cash used in financing activities was \$8.2 million for the nine months ended February 28, 2009 compared with cash provided by financing activities of \$3.0 million for the comparable prior year period. Cash used in financing activities for the nine months ended February 28, 2009 primarily consisted of payment of convertible note and long-term debt obligations of \$10.0 million offset by proceeds from the exercise of stock options and ESPP of \$1.8 million.

Our contractual obligations and their effect on liquidity and cash flows have not changed substantially from that disclosed in our Annual Report on Form 10-K for our fiscal year ended May 31, 2008 with the exception of the convertible debt, including interest totaling \$10.1 million and the \$6.8 million litigation settlement which were both paid in the first quarter of fiscal 2009. In addition, we paid a \$5.0 million installment in November 2008 in connection with the Oncobionic acquisition.

**Table of Contents**

In fiscal 2003, we financed an expansion of our headquarters and manufacturing facility with industrial revenue bonds for \$3.5 million. To secure this financing, we entered into agreements with local municipalities, a bank, a trustee and a remarketing agent. These agreements are referred to as the IDA agreements. The proceeds of the bonds were advanced as construction occurred. The bonds reprice every seven days and are resold by a Remarketing Agent. The bonds bear interest based on the market rate on the date the bonds are repriced and require quarterly principal payments ranging from \$25,000 to \$65,000 plus accrued interest through May 2022. We entered into an interest rate swap with a bank to convert the initial variable rate payments to a fixed interest rate of 4.45% per annum. The IDA agreements contain financial covenants relating to fixed charge coverage and interest coverage. The outstanding debt is collateralized by a letter of credit (\$2.4 million at February 28, 2009) and a first mortgage on the land, building and equipment comprising our facility in Queensbury, and we are required to pay an annual fee ranging from 1.0% to 1.9% of the outstanding balance depending on our financial results. The current fee is 1.0% and is in effect until August 22, 2009.

In fiscal 2007, we financed the expansion of our warehouse and manufacturing facility in Queensbury, New York. The expansion was financed principally with taxable adjustable rate notes (the Notes) issued by us aggregating \$5,000,000 and maturing in 2026. The Notes were issued under a trust agreement by and between us and a bank, as trustee (the Trustee). In connection with the issuance of the Notes, we entered into a letter of credit and reimbursement agreement (the Reimbursement Agreement) with the Bank that requires the maintenance of a letter of credit to support principal and certain interest payments on the Notes and requires payment of an annual fee on the outstanding balance. The current fee is 0.75% and is in effect until December 2009. We also entered into a remarketing agreement, pursuant to which the remarketing agent is required to use its best efforts to arrange for sales of the Notes in the secondary market. In connection with this financing, we entered into an interest rate swap agreement (the 2006 Swap Agreement) with the Bank, effective December 2006, with an initial notional amount of \$5,000,000, to limit the effect of variability due to interest rates on the rollover of the Notes. The 2006 Swap Agreement is a contract to exchange floating interest rate payments for fixed interest payments periodically over the life of the agreement without the exchange of the underlying notional amounts. The 2006 Swap Agreement requires us to pay a fixed rate of 5.06% and receive payments based on 30-day LIBOR repriced every seven days through December 2016. The Reimbursement Agreement contains certain financial covenants relating to fixed charge coverage and interest coverage, as defined. Amounts borrowed under the Reimbursement Agreement are collateralized by the aforementioned letter of credit and all of our assets. The debt covenants and the collateralization of substantially all of our assets to secure these financings may restrict our ability to obtain debt financing in the future.

During the nine months ended February 28, 2009, the Convertible Notes assumed in the acquisition of RITA on January 29, 2007 with an aggregate principal amount of \$9.7 million matured and were paid in cash.

On May 9, 2008, we completed the acquisition of all the issued and outstanding shares of capital stock of Oncobionic, Inc. pursuant to the terms of a stock purchase agreement entered into on October 12, 2006. The closing of the acquisition came as a result of the successful use of Oncobionic's irreversible electroporation (IRE) technology in the first human clinical trial for the treatment of soft tissue, conducted during the first week of April 2008. Under this stock purchase agreement, we agreed to pay a total purchase price of \$25.4 million, including \$400,000 of assumed liabilities. We made a payment of \$5.0 million upon the execution of the stock purchase agreement in October 2006. We paid \$10.0 million on May 9, 2008 upon the closing of the acquisition and \$5.0 million in November 2008. The remaining \$5.0 million is payable in November 2009.

We believe that our current cash and investment balances, together with cash generated from operations, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant additional acquisitions of other businesses or technologies for cash, we will, in all likelihood, require additional financing. We cannot assure you that such financing will be available on commercially reasonable terms, if at all.



**Table of Contents**

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to market risk from changes in interest rates on investments and financing that could impact our results of operations and financial position. Although we have entered into interest rate swaps with a bank to limit our exposure to interest rate change on our variable interest rate financings, we do not currently engage in any other hedging or market risk management tools.

At February 28, 2009, we maintained variable interest rate financing of \$7.1 million in connection with our facility expansions. We have limited our exposure to interest rate risk by entering into interest rate swap agreements with a bank under which we agreed to pay the bank fixed annual interest rate of 4.45% and 5.06% and the bank assumed our variable interest payment obligations under the financing.

Approximately 5% of our sales in the first nine months of fiscal 2009 were denominated in currencies other than the US dollar, primarily the Euro and GB pound.

Our excess cash is invested in highly liquid, short-term, investment grade securities with maturities primarily of less than two years. These investments are not held for speculative or trading purposes. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and marketable securities and therefore affect our cash flows and results of operations. We hold investments in auction rate securities ( ARS ) in order to generate higher than typical money market investments. ARS typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids. Such instances are usually the result of a drastic deterioration of issuer credit quality. Should there be a failed auction, we may be unable to liquidate our position in the securities in the near term. We have \$1.85 million in investments in two auction rate securities issued by New York state agencies that have failed auctions. The State of New York is current in its interest payments on the securities.

We are party to legal actions that arise in the ordinary course of business as described in Note L.

**Table of Contents**

**Item 4. Controls and Procedures.**

**Evaluation of Disclosure Controls and Procedures**

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us (including our consolidated subsidiaries) in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

**Changes in Internal Control over Financial Reporting**

There was no change in our internal control over financial reporting in the fiscal quarter ended February 28, 2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents**

**AngioDynamics, Inc. and Subsidiaries**

**Part II: Other Information**

**Item 1. Legal Proceedings.**

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our annual report on Form 10-K for the fiscal year ended May 31, 2008. We are party to other legal actions that arise in the ordinary course of business. We believe that any liability resulting from any currently pending litigation will not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows. The liability resulting from any currently pending litigation, could individually, or in the aggregate, have a material adverse effect on our results of operations or cash flows in the period settled.

**Table of Contents**

**Item 1A. Risk Factors.**

Item 1A, ( Risk Factors ) of our annual report on Form 10-K for our fiscal year ended May 31, 2008 sets forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. There have been no material changes from the Risk Factors described in our annual report on Form 10-K; however, those Risk Factors continue to be relevant to an understanding of our business, financial condition and operating results and, accordingly, you should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Submission Of Matters to a Vote of Security Holders.**

None.

**Item 5. Other Information.**

None.

**Table of Contents**

**Item 6. Exhibits.**

<b>No.</b>	<b>Description</b>
31.1	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.
31.2	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.
32.1	Certification of Chief Executive Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANGIODYNAMICS, Inc.

(Registrant)

Date: April 9, 2009

/s/ Johannes C. Keltjens  
Johannes C. Keltjens, President,  
Chief Executive Officer (Principal Executive Officer)

Date: April 9, 2009

/s/ D. Joseph Gersuk  
D. Joseph Gersuk, Executive Vice President,  
Chief Financial Officer (Principal Financial and Chief Accounting Officer)

**Table of Contents**

**EXHIBIT INDEX**

<b>No.</b>	<b>Description</b>
31.1	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.
31.2	Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934.
32.1	Certification of Chief Executive Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002